The Feasibility of Women at High Risk for Breast Cancer Participating in Chemoprevention Trials

References

• Bastian, L., Lipkus, I., Kuchibhatla, M., Weng, H., Halabi, S., Ryan, P., Skinner, C., and Rimer, B., 2001. Women's interest in chemoprevention for breast cancer, Archives of Internal Medicine 161 (2001), pp. 1639–1644.
   PubMed Web of Science ®Google Scholar
• Cull, A., Miller, H., Porterfield, T., Mackay, J., Anderson, E. D. C., Steel, C. M., and Elton, R. A., 1998. The use of videotaped information in cancer genetic counselling: A randomised evaluation study, British Journal of Cancer 77 (1998), pp. 830–837.
   PubMed Web of Science ®Google Scholar
• Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., et al., 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial, Journal of the American Medical Association 281 (1999), pp. 2189–2197.
   PubMed Web of Science ®Google Scholar
• Cuzick, J., 2000. A brief review of the current breast cancer prevention trials and proposals for future trials, European Journal of Cancer 36 (2000), pp. 1298–1302.
   PubMed Web of Science ®Google Scholar
• Evans, D., Lalloo, F., Shenton, A., Boggis, C., and Howell, A., 2001. Uptake of screening and prevention in women at very high risk of breast cancer, Lancet 358 (2001), pp. 889–890.
   PubMed Web of Science ®Google Scholar
• Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., et al., 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of the National Cancer Institute 90 (1998), pp. 1371–1388.
   PubMed Web of Science ®Google Scholar
• International Breast Cancer Intervention Study Investigators, 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial, Lancet 360 (2002), pp. 817–824.
   PubMed Web of Science ®Google Scholar
• Julian-Reynier, C. M., Bouchard, L. J., Evans, D. G., Eisinger, F. A., Foulkes, W. D., Kerr, B., Blancquaert, I. R., Moatti, J. P., and Sobol, H. H., 2001. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women, Cancer 92 (2001), pp. 959–968.
   PubMed Web of Science ®Google Scholar
• Kauff, N. D., Satagopan, J. M., Robson, M. F., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P., et al., 2002. Risk-reducing salpingo-oophorectomy inwomen with aBRCA1or BRCA2 mutation, New England Journal of Medicine 346 (2002), pp. 1609–1615.
   PubMed Web of Science ®Google Scholar
• Lovegrove, E., Rumsey, N., Harcourt, D., and Cawthorn, S. J., 2000. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer, Psycho-Oncology 9 (2000), pp. 193–202.
   PubMed Web of Science ®Google Scholar
• Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., Suthers, G., Haan, E., and Tucker, K., 2000. Intention to undergo prophylactic mastectomy in women at increased risk of developing hereditary breast cancer, Journal of Clinical Oncology 18 (2000), pp. 2250–2257.
   PubMed Web of Science ®Google Scholar
• Powles, T., and O'Brien, M., 1996. "The management of women with a high risk of breast cancer: The role of prophylactic tamoxifen". In: Eeles, R. A.B., Ponder, A. J., Easton, D. F., and Horwich, A., eds. Genetic predisposition to cancer. London: Chapman & Hall; 1996. pp. 267–281.
   Google Scholar
• Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J., and Davey, J., 1998. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet 352 (1998), pp. 98–101.
   PubMed Web of Science ®Google Scholar
• Pritchard, K. I., 1998. Is tamoxifen effective in prevention of breast cancer?, Lancet 352 (1998), pp. 80–81.
   PubMed Web of Science ®Google Scholar
• Ravdin, P., Fritz, N., Tormey, D., and Jordan, V., 1989. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen, Cancer Research 48 (1989), pp. 1026–1029.
   Web of Science ®Google Scholar
• Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. F., Evans, G., Isaacs, C., Daly, M. B., et al., 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, New England Journal of Medicine 346 (2002), pp. 1616–1622.
   PubMed Web of Science ®Google Scholar
• Rutqvist, L., 1999. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomized trial by the Cancer Research Campaign Breast Cancer Trials Group, The Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Groups and the Gruppo Interdisciplinare Valutazione Interventi in Oncolagia. Presented at Proceedings of the American Society of Clinical Oncology, 35th annual meeting. Atlanta, GA, 1999.
   Google Scholar
• Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., et al., 2002. Outcome and preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers, Journal of Clinical Oncology 20 (2002), pp. 1260–1268.
   PubMed Web of Science ®Google Scholar
• Veronesi, U., Maisonneuve, P., Costa, A., Sacchini, V., Maltoni, C., Roberston, C., Rotmensz, N., and Boyle, P., 1998. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women, Lancet 352 (1998), pp. 93–97.
   PubMed Web of Science ®Google Scholar